BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 11473732)

  • 21. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
    Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
    J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
    Patel S; Keller BA; Fisher LM
    Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
    Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
    Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
    Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
    Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
    Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
    Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ectopic expression of human topoisomerase IIalpha fragments and etoposide resistance in mammalian cells.
    Ernst AI; Soltermann A; Sigrist JA; Widmer L; Gasser SM; Stahel RA
    Int J Cancer; 2000 Oct; 88(1):99-107. PubMed ID: 10962446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
    Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
    Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
    Ritke MK; Yalowich JC
    Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
    Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
    Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
    Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.
    Campain JA; Gottesman MM; Pastan I
    Biochemistry; 1994 Sep; 33(37):11327-32. PubMed ID: 7727383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells.
    Jeon KH; Yu HV; Kwon Y
    Biochim Biophys Acta Gen Subj; 2018 May; 1862(5):1126-1133. PubMed ID: 29425806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
    Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
    J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.